Tirzepatide

Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs

Retrieved on: 
Tuesday, November 14, 2023

Loughborough, UK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, developer of a daily wear non-invasive glucose sensor, and digital healthcare programs today announced the UK launch of its ground-breaking approach to metabolic health and weight management by integrating continuous glucose monitoring (CGM) with its behavioral change program, Miboko, complemented by pharmaceutical interventions using GLP-1 agonists such as Ozempic, Wegovy and Mounjaro. This innovative offering, featuring education, lifestyle modifications, dietary guidance, exercise goals, and cutting-edge glucose monitoring, represents a significant advancement in personalized weight loss strategies addressing the metabolic health, obesity and diabetes markets.

Key Points: 
  • This innovative offering, featuring education, lifestyle modifications, dietary guidance, exercise goals, and cutting-edge glucose monitoring, represents a significant advancement in personalized weight loss strategies addressing the metabolic health, obesity and diabetes markets.
  • Nemaura's program leverages the power of its world-first daily wear non-invasive CGM technology, allowing individuals to gain insights into how their body deals with glucose.
  • In pilot studies with the UK's National Health Service (NHS), Nemaura's program has demonstrated encouraging outcomes.
  • The incorporation of GLP-1 agonists like Ozempic, Wegovy and Mounjaro adds a powerful layer of support for individuals seeking effective and sustainable weight loss.

Zepbound™ New Injectable Weight Loss Medication Coming to St. Louis

Retrieved on: 
Friday, November 10, 2023

St Louis, MO, Nov. 10, 2023 (GLOBE NEWSWIRE) -- The Food and Drug Administration has granted approval for Zepbound™, an innovative weight loss medication developed by Eli Lilly.

Key Points: 
  • St Louis, MO, Nov. 10, 2023 (GLOBE NEWSWIRE) -- The Food and Drug Administration has granted approval for Zepbound™, an innovative weight loss medication developed by Eli Lilly.
  • While Mounjaro is approved to treat Type 2 diabetes, Zepbound is the first tirzepatide medication approved specifically for weight loss.
  • He says, “the new class of injectable weight loss and diabetes medications, such as Ozempic, Wegovy, and Mounjaro, have revolutionized health and weight loss for patients in St. Louis.
  • “Up 70% of Americans struggle with obesity or excess weight,” he says, “and this new medication can allow people to take control of their health and find a weight loss solution that works for them.”

This Week in Health News: 11 Stories You Need to See

Retrieved on: 
Friday, December 8, 2023

NEW YORK, Dec. 8, 2023 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists covering the healthcare industry stay on top of the week's most newsworthy and popular releases, here's a roundup of stories from the week that shouldn't be missed.

Key Points: 
  • IASLC and LCRF have created this Team Science award to focus on furthering the development of novel therapies, including immunotherapeutic approaches, for patients with oncogene-driven lung cancers.
  • It is the intent of the two organizations to fund work that will have the potential to increase survivorship, and have a near-term benefit for these patients.
  • "Shifting to senior care is a significant decision, often filled with emotions and uncertainties," says Angela Olea, RN, Assisted Living Locators Founder, Brand President.
  • "The holidays, however, provide a natural setting to discuss and reassure our loved ones of our unwavering support throughout this transition."

FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems

Retrieved on: 
Wednesday, November 8, 2023

INDIANAPOLIS, Nov. 8, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Zepbound is indicated for adults with obesity (with a BMI of 30 kg/m2 or greater), or those who are overweight (with a BMI of 27 kg/m2 or greater) and also have weight-related medical problems such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease, to lose weight and keep it off. It should be used with a reduced-calorie diet and increased physical activity. Zepbound should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines, and it has not been studied in patients with a history of pancreatitis, or with severe gastrointestinal disease, including severe gastroparesis.

Key Points: 
  • "Obesity is a chronic disease that can result in serious health complications, including heart disease, stroke and diabetes.
  • Despite our knowledge of obesity as a treatable, chronic disease, people living with obesity still face many challenges in their health and weight management journey," said Joe Nadglowski, president and chief executive officer of the Obesity Action Coalition.
  • "New treatment options bring hope to the many people with obesity who struggle with this disease and are seeking better options for weight management."
  • Tirzepatide is also under regulatory review for weight management in Europe, China, the United Kingdom and several additional markets.

Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023

Retrieved on: 
Tuesday, October 17, 2023

“These data point to the potential of CRB-913, both as a monotherapy in combination with incretin therapies,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.

Key Points: 
  • “These data point to the potential of CRB-913, both as a monotherapy in combination with incretin therapies,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.
  • CRB-913 demonstrated markedly enhanced plasma exposure and markedly reduced brain levels compared to the first generation CB1 inverse agonist rimonabant.
  • Concomitantly, improvements were observed in body fat content, leptinemia, insulin resistance, liver triglycerides, liver fat deposits and liver histology.
  • Investigators concluded that CRB-913, in combination with incretin analogs, could potentially deliver meaningful improvements in obesity and related conditions.

Lilly Announces Leadership Transitions

Retrieved on: 
Wednesday, October 4, 2023

INDIANAPOLIS, Oct. 4, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced changes to its executive leadership team.

Key Points: 
  • INDIANAPOLIS, Oct. 4, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced changes to its executive leadership team.
  • Mike Mason, executive vice president and president of Lilly Diabetes and Obesity, will retire from Lilly at the end of 2023 after 34 years with the company.
  • Patrik Jonsson will assume leadership of Lilly Diabetes and Obesity as executive vice president and president, effective January 1, 2024, in addition to his current responsibility as executive vice president and president of Lilly USA.
  • A 33-year Lilly veteran with strong US and international commercial experience, Jonsson also has led Lilly Immunology and Lilly Bio-Medicines, as well as served as the general manager of Lilly Sweden, Scandinavia, Italy and Japan.

AMRA Used in Tirzepatide Analyses Evaluating the Effect on Muscle Composition via MRI

Retrieved on: 
Tuesday, October 3, 2023

Two analyses have shed light on an important factor when evaluating treatments that significantly reduce bodyweight: their effect on muscle composition.

Key Points: 
  • Two analyses have shed light on an important factor when evaluating treatments that significantly reduce bodyweight: their effect on muscle composition.
  • For their multicenter SURPASS-3 MRI study, Eli Lilly and Company selected AMRA® Researcher to measure muscle volume and muscle fat infiltration.
  • The two analyses presented at the European Association for the Study of Diabetes (EASD) annual meeting this year aim to better understand the effect of tirzepatide on muscle composition.
  • The second analysis examined the effect of tirzepatide on muscle composition (both muscle fat infiltration and muscle volume) using longitudinal data from the UK Biobank imaging study to contextualize the observed changes.

Drug Shortages Impacting Nearly All Pharmacies, Pharmacy Technician Certification Board Survey Finds

Retrieved on: 
Thursday, September 21, 2023

WASHINGTON, Sept. 21, 2023 /PRNewswire/ -- In a recent online survey conducted by the Pharmacy Technician Certification Board (PTCB) of Certified Pharmacy Technicians (CPhTs) who hold PTCB's Supply Chain and Inventory Management Certificate , nearly 96 percent of respondents said their pharmacy faces drug shortages.

Key Points: 
  • WASHINGTON, Sept. 21, 2023 /PRNewswire/ -- In a recent online survey conducted by the Pharmacy Technician Certification Board (PTCB) of Certified Pharmacy Technicians (CPhTs) who hold PTCB's Supply Chain and Inventory Management Certificate , nearly 96 percent of respondents said their pharmacy faces drug shortages.
  • Pharmacy Technician Certification Board (PTCB) survey shows nearly all pharmacies facing disruptive drug shortages.
  • When a comparable drug is not available, pharmacy technicians utilize their pharmacy's compounding services (28.79%) or refer to another compounding pharmacy (6.06%).
  • "It's no surprise that pharmacy technicians are actively working on solutions to mitigate drug shortages for their patients.

Polypeptide.ltd Announces Intent to Expand Tirzepatide and Retatrutide to Production Capacity of High-Quality Peptides.

Retrieved on: 
Wednesday, August 16, 2023

Leading peptide manufacturer accelerates delivery of advanced peptides to global researchers

Key Points: 
  • Moscow, Russia--(Newsfile Corp. - August 16, 2023) - Polypeptide.ltd , a frontrunner in delivering exceptional peptide services, proudly announces a substantial expansion of its production capacity.
  • This strategic move enables expedited delivery of high-quality Tirzepatide and Retatrutide to researchers worldwide.
  • On the other hand, Tirzepatide is used to treat type 2 diabetes.
  • With the enhanced capacity to produce the two advanced peptides, Polypeptide.ltd is equipped with HPLC, GC, and other analytical instruments and strictly according to cGMP standards.

Lilly's SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes

Retrieved on: 
Saturday, June 24, 2023

INDIANAPOLIS, June 24, 2023 /PRNewswire/ -- Detailed results from SURMOUNT-2, a phase 3 clinical trial evaluating the efficacy and safety of Eli Lilly and Company's (NYSE: LLY) tirzepatide (10 mg and 15 mg) for chronic weight management in participants with obesity or overweighti and type 2 diabetes, showed that tirzepatide led to superior weight reduction versus placebo for both doses. The data were presented during a symposium at the American Diabetes Association's® (ADA) 83rd Scientific Sessions and were simultaneously published in The Lancet.

Key Points: 
  • The data were presented during a symposium at the American Diabetes Association's® (ADA) 83rd Scientific Sessions and were simultaneously published in The Lancet .
  • Tirzepatide met both co-primary endpoints and all key secondary endpoints compared to placebo for both estimands, with those taking tirzepatide achieving a mean weight reduction of 13.4% (29.8 lb.
  • or 3.2 kg) on placebo for the efficacy estimand, which evaluates the treatment effect if all participants adhered to treatment.
  • Regulatory action for the U.S. submission for tirzepatide in adults with obesity, or overweight with weight-related comorbidities is expected by the end of 2023.